Organovo Holdings, Inc.
ONVO
|
$1.11
-3.48%
-3.6%
280K
|
Health Technology
(0.0% 1d) (6.8% 1m) (-46.3% 1y) (0.0% 2d) (-1.8% 3d) (-18.5% 7d) (-49.93% volume)
Earnings Calendar:
Market Cap: $ 11,144,482
http://www.organovo.com
Sec Filling | Patents | 6 employees
Organovo Holdings, Inc. engages in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company was founded in April 2007 and is headquartered in San Diego, CA.
add to watch list Paper trade email alert is off
Press-releases
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
ONVO | $1.11 -3.48% -3.6% 280K
|
Health Technology
|
| O: 64.34%
H: 4.82%
C: -18.67%
fxr314 metabolic liver positive for results
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
Published: 2024-01-25 (Crawled : 13:00) - globenewswire.com
ONVO | $1.11 -3.48% -3.6% 280K
|
Health Technology
|
| O: -0.97%
H: 0.98%
C: -0.98%
fxr314 congress fibrosis show
3D Bioprinting in Medical Market to Reach $4.9 Billion, Globally, by 2032 at 15.5% CAGR: Allied Market Research
Published: 2024-01-22 (Crawled : 06:00) - prnewswire.com
DDD F | $3.55 2.31% 0.0% 1.5M
|
Producer Manufacturing
|
| O: 1.64%
H: 7.04%
C: 3.62%
ONVO | $1.11 -3.48% -3.6% 280K
|
Health Technology
|
| O: 2.0%
H: 2.94%
C: 0.0%
reach research medical market
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
Published: 2024-01-09 (Crawled : 13:00) - globenewswire.com
ONVO | $1.11 -3.48% -3.6% 280K
|
Health Technology
|
| O: -1.79%
H: 10.0%
C: 3.64%
fxr314 congress
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
Published: 2023-12-06 (Crawled : 13:00) - globenewswire.com
ONVO | $1.11 -3.48% -3.6% 280K
|
Health Technology
|
| O: -0.83%
H: 0.83%
C: -5.25%
fxr314 results nash
CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
Published: 2023-11-13 (Crawled : 13:00) - globenewswire.com
ONVO | $1.11 -3.48% -3.6% 280K
|
Health Technology
|
| O: 0.0%
H: 6.67%
C: 5.93%
fxr314 potential therapy
Organovo Highlights FXR314 Combination Therapy Potential and Plan
Published: 2023-11-08 (Crawled : 13:00) - globenewswire.com
ONVO | $1.11 -3.48% -3.6% 280K
|
Health Technology
|
| O: 2.45%
H: 1.06%
C: -7.45%
fxr314 potential therapy
Organovo to Participate in the H.C. Wainwright Global Investment Conference
Published: 2023-09-08 (Crawled : 17:00) - globenewswire.com
ONVO | $1.11 -3.48% -3.6% 280K
|
Health Technology
|
| O: 0.93%
H: 1.83%
C: 1.83%
conference global
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
Published: 2023-08-23 (Crawled : 12:00) - globenewswire.com
ONVO | $1.11 -3.48% -3.6% 280K
|
Health Technology
|
| O: 6.98%
H: 0.0%
C: -1.45%
fxr314 nash phase 2
Organovo Announces FXR Program
Published: 2023-03-21 (Crawled : 12:20) - globenewswire.com
ONVO | $1.11 -3.48% -3.6% 280K
|
Health Technology
|
| O: 0.0%
H: 7.37%
C: 1.58%
program
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10